Tags: Online Gambling 888 adds former William Hill CFO to board AddThis Sharing ButtonsShare to LinkedInLinkedInShare to FacebookFacebookShare to TwitterTwitter Subscribe to the iGaming newsletter 888 Holdings has appointed Mark Summerfield, the former interim chief financial officer of William Hill, to its board as an independent non-executive director.Joining 888 with immediate effect, Summerfield will also become chairman of the operator’s audit committee, serving alongside other members Zvika Zivlin and Anne de Kerckhove.Summerfield acted as interim CFO at William Hill from July 2016 and December 2017. He also served as a partner at multinational professional services network KPMG between October 1999 to May 2017.During his time with KMPG, Summerfield held various senior roles such as global head of gaming, UK head of audit for technology, media and telecoms, and UK head of assurance. He was also a partner at KPMG between May 2003 and October 2005.“With his extensive experience working with boards and audit committees of major listed companies, Mark brings a wealth of experience to 888,” 888 chairman, Brian Mattingley, said. “This will be of considerable benefit as the company continues to grow and pursue its strategic objectives. “He will be a valuable addition to the board and the audit committee and I am delighted that he has agreed to join us.” People 6th September 2019 | By contenteditor 888 Holdings has appointed Mark Summerfield, the former interim chief financial officer of William Hill, to its board as an independent non-executive director and chairman of its audit committee. Topics: People Strategy Email Address
Enter Your Email Address Jabran Khan | Tuesday, 21st July, 2020 | More on: ITV This FTSE 100 household name represents a bargain currently trading at less than 70p per share! I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. “This Stock Could Be Like Buying Amazon in 1997” Image source: Getty Images I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Many companies in the FTSE 100 have been left reeling in the Covid-19 pandemic. During the lockdown, demand for television services has increased exponentially. The ‘stay at home’ advice has benefitted the streaming industry. It is estimated there were nearly 6m new subscribers to streaming services during the lockdown period. 5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…Seen as a more traditional television operator, ITV (LSE:ITV) has seen its share price fall below the 70p per share mark. I love a contrarian buy and feel ITV falls into that category right now. You would have to go back to 2011 to pick up ITV shares at the current price. FTSE 100 bargainITV’s business model is split into two main categories. The broadcast division of the company runs numerous ITV channels, including its flagship channel ITV1. Its other division is ITV Studios, the largest commercial producer in the UK. The studio produces content for its own channels as well as other UK broadcasters. Additionally the studio division has US and other international arms, which further expands its reach.ITV’s 2019 full-year results show that broadcast generated over 60% of its profits. The FTSE 100 incumbent made an operating profit of £535m on revenue of £3,308m in total. This equates to an above average and (in my opinion) impressive operating margin of 16%. I think that the studio side of the business is where the longer-term value lies. ITV’s unique ability to produce quality content regularly bought by its rivals points towards a long-term opportunity for further growth and success.Year-to-date, ITV’s share price has fallen nearly 60% which could be seen as problematic. I do not see it that way, myself. The market crash has devastated share prices across the FTSE. Trading updateThe coronavirus lockdown has affected most FTSE companies, which has prompted the cancellation of many advertising campaigns. ITV were affected by this. It reporting a drop of over 40% in advertising demand in April alone in its first-quarter trading update at the end of May. ITV saw external revenue down by 7% and ITV Studios revenue was down by 11%. On the other hand, broadcast revenue was up 2%, as was overall total viewing, by 2% during this period. A take away for me was that ITV experienced its best quarter since 2009 in terms of ITV1’s share of viewing percentage of 17.9%. In my eyes this means ITV does possess good broadcast and studio content that entices viewership to return for more.VerdictWith restrictions easing throughout the country I believe that ITV will see an upturn in advertising demand and overall fortunes. Furthermore ITV Studios will be able to continue to produce new content to add to its extensive backlog in the vault.I would consider ITV a great opportunity to pick up shares in a well established company that has consistently made profit. Profit will be affected for the current year due to the pandemic, however, most FTSE 100 companies are in a similar position. ITV has plenty of cash to see it through this tough period as well as a healthy balance sheet. Don’t be put off by a cancelled dividend for 2019 – many other businesses throughout the FTSE have adopted this strategy to preserve liquidity in these uncertain times.ITV would sit in my buy and hold category. It wouldn’t surprise me if this time next year ITV’s share price has more than doubled. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Our 6 ‘Best Buys Now’ Shares Simply click below to discover how you can take advantage of this. See all posts by Jabran Khan
Royston Wild | Sunday, 22nd November, 2020 “This Stock Could Be Like Buying Amazon in 1997” Forget Cash ISAs! I’ll be building a £1m Stocks and Shares ISA with UK shares in 2021 It might seem mighty tempting to stash your savings in a Cash ISA today. UK share markets have endured a wild time in 2020 as the coronavirus crisis has persisted. As a consequence a great many stock pickers have seen the value of their investments fall off a cliff.None of this matters to me, however. Nor does the possibility of more volatility in 2021. I’ll continue to invest in my Stocks and Shares ISA despite the gloomy economic outlook.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…Cash vs UK sharesFans of cash products like Cash ISAs like the peace of mind that they apparently provide. If I invested £20,000 at the start of the year I’d still have that (possibly some accrued interest, too) to call upon today.Let’s say I’d invested in something like a FTSE 100 tracker fund instead. Britain’s blue chip UK share index is down 16% from the start of 2020. This means that my £20,000 on 1 January would have been whittled down to approximately £16,800. Plummeting dividend payments in 2020 mean that income flows from that tracker wouldn’t have taken much of the sting out of that huge fall either.Awful cash returnsThis would cause a colossal problem if I wanted to draw on that cash today. But I don’t. I buy UK shares with a view to holding them for at least a decade. Over this sort of timeframe it’s been proven that products like Stocks and Shares ISAs provide much meatier returns than their cash equivalents.Interest rates from Cash ISAs over the past decade have lagged their historical norms by a large distance. And things have taken a turn for the worse this year as Threadneedle Street cut rates to record lows following the economic downturn.As a consequence, the best-paying instant-access Cash ISA on the market offers an interest rate of just 0.95%. It’s unlikely that rates will improve from Cynergy Bank’s market-leading product any time soon, either. Ultra-low Bank of England benchmark rates appear here to stay. It’s possible they might even turn negative. This is why investing in UK shares is a much better way to use one’s cash today.Sticking with stocksLet’s assume that Cynergy Bank’s rates remain in place for the next decade. Someone who saves £300 a month in that Cash ISA can expect to make around £37,740 in that time.By comparison, someone who invested that money in UK shares could have expected to have made as much as £59,960 by 2031. This is because the average yearly return sits at between 8% and 10% for long-term investors.But that £22,000-plus difference is chicken feed compared to the gulf that can emerge after three-and-a-half decades of saving. A Cash ISA saver aged 30 can expect to have made around £149,300 by the time they’re 65, based on that 0.95% interest rate. They could have made a cool £1.02m if they’d invested that £300 a month in a Stocks and Shares ISA instead. It’s no exaggeration to describe the difference between those two sums as life changing.As I say, 2020 has been a tough time for UK share pickers. But the economy will bounce back eventually and so will stock markets. In fact, those that invest after the recent stock market crash can supercharge their returns. Experts like The Motley Fool are here to tell you how. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Enter Your Email Address I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Our 6 ‘Best Buys Now’ Shares I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. See all posts by Royston Wild Simply click below to discover how you can take advantage of this. Image source
LATEST RUGBY WORLD MAGAZINE SUBSCRIPTION DEALS So if that skip were to turn into a leap of faith for those players not so familiar to the Australians it must be considered that some internationals who have played well in the last few seasons have never played Australia.Selection up in the air: Scot Sean MaitlandTim Visser, for example, was in the crowd the day that Scotland beat the Wallabies in Newcastle in 2012, having been just shy of the day when he qualified to play in dark blue. He is now a must-pick winger. On the opposite wing for Scotland is also Sean Maitland, who impressed in his first season in the 6 Nations. Australians have seen him play for the Canterbury Crusaders, but never on an international stage.Craig Gilroy has also impressed in his first season with Ireland. Arguably he would not get a look in for the Irish were Bowe healthy and considered, but that has not hampered Gilroy as he has run in support and scampered out of the line well. Simon Zebo, too, has a chance and with the flashes of unbridled creativity he has offered, the Munsterman bears keeping in thought.Then, of course, are the long shots thrown into consideration because they have caught fire in the last month or more. David Strettle is in fine fettle with Saracens, offering a foil across the park from Ashton. The Aviva Premiership’s top try scorer Tom Varndell could also be bandied about for that same reason, and his name is certainly considered on bookmakers’ lists. during the RBS Six Nations match between England and Scotland at Twickenham Stadium on February 2, 2013 in London, England. Then, after these men, the name most are blurting in a high pitch is that of Christian Wade.The Wasp has the nimble feet and explosive turn that enthrals crowds and causes defenders to melt like butter in the sun. He may have question marks over his defensive abilities and he may not have experienced tension away from his familiar cabal of friends, but he has a spark. The argument states that with the Lions, even a little spark can cause the whole tour to catch alight. Worth the risk?: Despite the myriad question marks over his head, many want Christian Wade taken as a Lions bolterBy Alan DymockIN THE aftermath of the Six Nations and with time running out we are all confronted with the starkest of choices: who are our Lions?An obvious point of conjecture, there were at least some standouts in recent weeks. So in the interest of making clear what Warren Gatland, Graham Rowntree, Rob Howley and Andy Farrell face before the squad announcement on 30 April, Rugby World will sift through runners and riders in each key position.The twin terrors: Wales’ deadly duo, North and CuthbertOne of which, that of the wingers, must scare the life out of the bookmakers.In this position more than any other there is scope for Gatland to throw caution in front of an industrial fan and scatter his thoughts. Yes, of course, there are the dual threats of George North and Alex Cuthbert of Wales who are both potent, expeditious and fond of a dot down. Nevertheless, without the bankable pair there is a fine opportunity for a curve ball, with Australia likely to be spooked or confused by the names pulled out of a hat by the selection committee.The Wallabies are well aware of Chris Ashton and Tommy Bowe. They have seen Ashton at his best – burning through the Australian defence like a tenner in teenagers pocket in 2010 – but they have also seen him at his worst in their recent jaunt north. Selecting him would represent somewhat of a leap of faith, while Bowe, who was part of the Ireland team that beat Australia at the 2011 World Cup, is not long off the physio table, but has made an eye-catching return with two tries in three appearances.
CANADA: Primate asks prime minister to restore Gaza hospital funding Middle East TryTank Experimental Lab and York St. John University of England Launch Survey to Study the Impact of Covid-19 on the Episcopal Church TryTank Experimental Lab Bishop Diocesan Springfield, IL Rector Shreveport, LA Director of Administration & Finance Atlanta, GA Virtual Episcopal Latino Ministry Competency Course Online Course Aug. 9-13 Priest-in-Charge Lebanon, OH Israel-Palestine, By Ali SymonsPosted Jun 26, 2012 Youth Minister Lorton, VA Submit a Press Release Featured Events Submit a Job Listing AddThis Sharing ButtonsShare to PrintFriendlyPrintFriendlyShare to FacebookFacebookShare to TwitterTwitterShare to EmailEmailShare to MoreAddThis Seminary of the Southwest announces appointment of two new full time faculty members Seminary of the Southwest Rector and Chaplain Eugene, OR Episcopal Charities of the Diocese of New York Hires Reverend Kevin W. VanHook, II as Executive Director Episcopal Charities of the Diocese of New York Associate Rector for Family Ministries Anchorage, AK The Church Investment Group Commends the Taskforce on the Theology of Money on its report, The Theology of Money and Investing as Doing Theology Church Investment Group June 26, 2012 at 5:44 pm Thank you to Archbishop Hiltz for adding your voice to the outcry of support for those struggling in Gaza. Please add yours! Curate (Associate & Priest-in-Charge) Traverse City, MI Rector Tampa, FL Episcopal Church releases new prayer book translations into Spanish and French, solicits feedback Episcopal Church Office of Public Affairs Assistant/Associate Priest Scottsdale, AZ Virtual Celebration of the Jerusalem Princess Basma Center Zoom Conversation June 19 @ 12 p.m. ET Assistant/Associate Rector Washington, DC Rector (FT or PT) Indian River, MI New Berrigan Book With Episcopal Roots Cascade Books Tags Remember Holy Land Christians on Jerusalem Sunday, June 20 American Friends of the Episcopal Diocese of Jerusalem Anne Lynn says: The Church Pension Fund Invests $20 Million in Impact Investment Fund Designed to Preserve Workforce Housing Communities Nationwide Church Pension Group Featured Jobs & Calls Course Director Jerusalem, Israel Submit an Event Listing Episcopal Migration Ministries’ Virtual Prayer Vigil for World Refugee Day Facebook Live Prayer Vigil June 20 @ 7 p.m. ET Canon for Family Ministry Jackson, MS Rector Hopkinsville, KY Rector Bath, NC Missioner for Disaster Resilience Sacramento, CA Al Ahli Arab Hospital in Gaza City[Anglican Church of Canada] Archbishop Fred Hiltz, primate of the Anglican Church of Canada, has asked Prime Minister Stephen Harper to re-commit funds to the United Nations Relief and Works Agency so it can continue to support Al Ahli Arab Hospital in Gaza City, Gaza Strip. The hospital is run by the Episcopal Diocese of Jerusalem and serves about a million people, regardless of religious or ethnic background.“So many people are turning to us in desperation,” wrote Hiltz in his letter to Harper. “Let us not be blind to their suffering nor deaf to their cry.”Suhaila Tarazi, hospital director, recently informed Diocese of Jerusalem partners that UNRWA abruptly had ended its financial contractual support of the hospital in May. The reason given for this decision was UNRWA’s diminished budgets due to non-payment of pledges from donor countries.In his letter to Harper, Hiltz wrote, “UNRWA, not Hamas, nor the Palestinian authority is the sole provider of education and emergency medical services to 2/3 of the population of Gaza who are refugees.”The Ahli Arab Hospital has a capacity of 80 beds with an occupancy rate around 78.60%. Its departments include general surgery, internal medicine, emergency and ambulance services, orthopedics, urology, gynecology, and obstetrics.The hospital also provides free medical missions to the poor twice weekly, specialized free clinics for chronically ill elderly women, and free care for burn injuries and underweight or malnourished children.“The hospital is a haven of peace in the middle of one of the world’s most troubled places,” said Dr. Andrea Mann, General Synod’s global relations coordinator.“All aspects of life in Gaza are affected by the political situation between Israel and Palestine, especially through restrictions on the movement of materials, medicines and people. Yet, Al Ahli Arab Hospital continues to provide some of the finest medical care available in the region.”Both Hiltz and Mann have visited the hospital and observed the work of volunteers and staff.The Anglican Church of Canada contributes to the Ahli Arab Hospital as well as other ecumenical services to Palestinian refugees in Gaza and elsewhere. Soon General Synod will strengthen overall assistance to diocesan health ministries.Bishop Suheil Dawani, Diocese of Jerusalem, and Archbishop Hanna Mouneer, Province of Jerusalem and the Middle East, have commended the Primate’s letter and this prayer to all supporters:“O God of wholeness and healing, we lift up the staff and patients of the Ahli Arab Hospital in Gaza. Strengthen and guide management and staff as they treat the poor and injured, especially in this time of deep crisis and uncertain future. Bless the patients who receive care with Your healing touch. Give us all a renewed awareness of the blessing of health and grant us courage to support Ahli Arab Hospital in its work.”The full text of the Primate’s letter is below.— Ali Symons is General Synod web writer for the Anglican Church of Canada.____________________________________________________________June 20, 2012The Honourable Stephen Joseph Harper, P.C., M.P.Prime Minister of CanadaLangevin Block80 Wellington StreetOttawa, OntarioK1A 0A2Dear Prime Minister:As Primate of the Anglican Church of Canada I write out of concern for the termination of United Nations Relief and Works Agency (UNRWA) support for the Al Ahli Arab Hospital, Gaza. This hospital is an Anglican health centre of the Episcopal Diocese of Jerusalem and non-sectarian in its services. Having visited the hospital in 2009 with The Rt. Rev. Suheil Dawani, the Anglican Bishop in Jerusalem, I can attest to the truth that this facility provides care without prejudice to any religious or ethnic community, or irrespective of gender, social class or political affiliation. Staff are very competent and extraordinarily devoted. The consequences of the hospital’s closure are devastating for more than one million people, of whom more than half are women and children in desperate need of emergency care and primary treatment.The Government of Canada and the Anglican Church of Canada have for many years been important sources of support for the valuable work of the Al Ahli Arab Hospital. The Government of Canada continues to commit funds to UNRWA’s Emergency Fund. Likewise, the Anglican Church of Canada continues funding for ecumenical services to Palestinian refugees in Gaza and elsewhere, and will soon strengthen overall assistance to diocesan health ministries.UNRWA, not Hamas, nor the Palestinian Authority, nor any other government is the sole provider of education and emergency medical services to 2/3 of the population of Gaza who are refugees. Not unlike Canadian provinces, UNRWA designates more than half of its budget to education and health care.Prime Minister, I ask you to re-commit Canada to the generous funding of UNRWA, and to its 2012 emergency programs in Gaza, so the Al Ahli Arab Hospital is restored to full service. I urge you to act expeditiously.Please know of my thanks anticipating your willingness to act with compassion in this matter of urgent humanitarian need. So many people are turning to us in desperation. Let us not be blind to their suffering nor deaf to their cry.With respect,I am,Sincerely in Christ,Fred J. HiltzArchbishop and PrimateCc: The Honourable John Baird, Minister of Foreign Affairs; UNRWA;The Rt. Rev. Suheil Dawani, Episcopal Diocese of JerusalemThe Most Rev. Dr. Mouneer Hanna Anis, The Episcopal Church in Jerusalem and the Middle East. Press Release Service Ya no son extranjeros: Un diálogo acerca de inmigración Una conversación de Zoom June 22 @ 7 p.m. ET An Evening with Aliya Cycon Playing the Oud Lancaster, PA (and streaming online) July 3 @ 7 p.m. ET Director of Music Morristown, NJ Inaugural Diocesan Feast Day Celebrating Juneteenth San Francisco, CA (and livestream) June 19 @ 2 p.m. PT Rector Pittsburgh, PA In-person Retreat: Thanksgiving Trinity Retreat Center (West Cornwall, CT) Nov. 24-28 Cathedral Dean Boise, ID Rector Smithfield, NC Associate Priest for Pastoral Care New York, NY Rector Washington, DC Assistant/Associate Rector Morristown, NJ Associate Rector Columbus, GA Rector Knoxville, TN Rector/Priest in Charge (PT) Lisbon, ME Comments (1) Curate Diocese of Nebraska Anglican Communion, Priest Associate or Director of Adult Ministries Greenville, SC Comments are closed. Rector Albany, NY Rector Belleville, IL Rector Collierville, TN Rector Martinsville, VA An Evening with Presiding Bishop Curry and Iconographer Kelly Latimore Episcopal Migration Ministries via Zoom June 23 @ 6 p.m. ET Family Ministry Coordinator Baton Rouge, LA Join the Episcopal Diocese of Texas in Celebrating the Pauli Murray Feast Online Worship Service June 27 This Summer’s Anti-Racism Training Online Course (Diocese of New Jersey) June 18-July 16
Area: 516100 m² Year Completion year of this architecture project Spain Architects: Estudi PSP Arquitectura Area Area of this architecture project Elderly Residence Mas Piteu / Estudi PSP ArquitecturaSave this projectSaveElderly Residence Mas Piteu / Estudi PSP Arquitectura ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/248216/elderly-residence-mas-piteu-estudi-psp-arquitectura Clipboard Save this picture!© Francisco Urrutia+ 20 Share “COPY” “COPY” ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/248216/elderly-residence-mas-piteu-estudi-psp-arquitectura Clipboard Year: Residential Architecture CopyResidential Architecture•Barcelona, Spain ArchDaily Elderly Residence Mas Piteu / Estudi PSP Arquitectura Projects 2011 Photographs Photographs: Francisco Urrutia Save this picture!© Francisco UrrutiaRecommended ProductsFiber Cements / CementsRieder GroupFacade Panels – concrete skinFiber Cements / CementsEQUITONEFiber Cement Facade Panel NaturaSkylightsFAKROWooden pivot roof windows FYP-V proSkyFiber Cements / CementsSwisspearlSwisspearl Largo Fiber Cement Panels Save this picture!section Save this picture!© Francisco UrrutiaThe Elderly Residence, located on the outskirts of Barcelona, aims to solve the transition from an urban area to the Collserola Park. The building shows like an organic volume adapted to the topography, the landscape and the pre-existences. The overhangs reinforce the concept of the ground and the vegetation passing under the building. The pre-existing stone arches and retaining walls determine the main entrance to the new building and also its height. These listed elements are one of the most important features in the project. The level on top of the preserved wall is the boundary between two different parts of the building, one leaning into the other. The stone lower volume comprises ground floor and mezzanine, and hosts main entrances and amenities. The white overhanging volume contains the two bedroom floors, divided by curved corridors. A small listed old house in the plot has been also included in the project. It has been completely refurbished, and houses four rooms for non-handicapped customers. These extra quality rooms have even an independent entrance.Project gallerySee allShow lessBrazza Nord Bordeaux Masterplan / KCAPArticlesShan Shui Grape Garden – Yanqing Wine Park, Greenhouse and Winery / LocalDesignStudioArticlesProject locationAddress:Barcelona, SpainLocation to be used only as a reference. It could indicate city/country but not exact address. Share CopyAbout this officeEstudi PSP ArquitecturaOfficeFollowProductConcrete#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureBarcelonaResidentialHousingSpainPublished on June 28, 2012Cite: “Elderly Residence Mas Piteu / Estudi PSP Arquitectura” 28 Jun 2012. ArchDaily. Accessed 11 Jun 2021.
Advertisement Tagged with: Funding Howard Lake | 3 July 2008 | News AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis European Cultural Foundation overhauls grants programme About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving. 41 total views, 1 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis The European Cultural Foundation (ECF) is completely overhauling its grants programmes. The programmes are easier to understand, with a simple split between grants for individuals and grants for organisations. And application forms will be a thing of the past. The Foundation is an independent body that promotes cultural diversity, artistic creation and collaboration across Europe. The first grant scheme to benefit from the overhaul is the Artistic Projects scheme, which supports cutting edge work by organisations and individuals that provide new insights into Europe’s 21st century cultural diversity. Applications from individuals and organisations new to the Foundation are especially welcomed. Grants will range from €30,000 to €60,000.Who can apply for Artistic Project grants?Applications are invited from individual artists and organisations working in any artistic discipline. Individual artists must have a demonstrable track record, with at least 5 years experience in their chosen discipline. Applicants can come from within Europe or outside of it, but all projects must relate to Europe and its diversity.What can you apply for?Projects must be new and at their initial phase. They must show artistic originality and European relevance. All projects must be completed no later than 18 months after the grants contract has been signed, which is likely to be during November 2008.Priority will be given to new applicants and for:• Projects exploring a wide spectrum of European diversity: from the co-existence of traditions and peoples in one place, to migration movements and new urban, globalised diversity.• Projects reflecting on Europeanness and European developments in an innovative way. Artists will need to comment, research, question, imagine and visualise what is happening in European society, in the cities, among and within communities, across and beyond European borders.• Projects involving an innovative creative process and a visible end product. The Foundation is looking for artistic impressions, ideas, answers, works on how Europe should/could relate to the diversity in its communities.• Projects that have a legacy for the future. One-off projects may still be eligible provided they can demonstrate a vision for a lasting impact in their context.Projects should be predominantly non profit making, though some commercial element is permissible.How to apply.There is a brief online application sheet, and this should accompany a simple two-page (1000 words) description of who will be involved and what form the project will take and why.Within a few weeks of the application deadline successful initial applicants will be invited to provide more information and will have about a month to do so.More information.The basic details of the scheme and access to the online application sheet are available atwww.eurocult.org/we-support-cultural-cooperation/grants/guidelines-for-artistic-grants/You can also contact:European Cultural Foundation (ECF)Jan van Goyenkade 51075 HN AmsterdamThe NetherlandsTel.: 00 31 20 573 38 68.E-mail: [email protected] date: 1 September 2008.This information is provided by Fundinginformation.org, the online news, information and support service for fundraisers and funding advisers throughout the UK. For subscription details go towww.fundinginformation.org
Attitudes to legacy giving shifting with 4 in 10 now happy to leave a gift to charity Advertisement AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis22 Tagged with: legacies legacy fundraising 290 total views, 2 views today 291 total views, 3 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis22 Melanie May | 24 May 2019 | News Remember A Charity’s latest consumer tracking poll has found that four in ten people now say they would be happy to leave a gift to charity in their Will, up from 35% in 2008.The OnePoll survey commissioned by Remember A Charity and conducted during March and April this year found that 40% of people aged 40+ would be happy to give a small percentage of their estate to charity, up from 35% in 2008. Almost two thirds (65%) said that it was acceptable to leave your entire estate to charity if you wish.The large majority (70%) of respondents felt that people should tell their children if they intended to leave a ‘reasonable sum of money’ to charity in their Will. Only one in four (26%) thought their family would object to them making such a gift, down from 31% in 2008.In 2008, the majority of respondents said that it was better to give money when you are alive than through a legacy (63%) and that close relatives have a right to the majority of an estate (72%). Today, according to the latest survey findings, those views are held by less than half, at 47% and 41% respectively.Rob Cope, Director of Remember A Charity, said:“We’ve seen a real shift in attitudes in recent years with the public indicating that they are more open to the concept of legacy giving and this is a positive sign for the years ahead.“While legacy income will inevitably fluctuate to reflect wider economic trends, the public’s propensity to give is the key driving factor for market growth. This poll suggests not only that the public is more willing to leave a gift, but that they have a clearer understanding of legacy giving and think people should be free to do what they want with their estates.“People still do worry about how their family might feel if they leave a charitable gift in their Will and this underlines the importance of encouraging potential legators to discuss their wishes with their family, reducing the risk of dispute.”The challenge now for Remember A Charity, Cope added, and a key pillar of its new three-year strategy, is to review what can be done to shift the emphasis on from building awareness to inspiring supporters into taking action and writing charitable gifts into their Wills. About Melanie May Melanie May is a journalist and copywriter specialising in writing both for and about the charity and marketing services sectors since 2001. She can be reached via www.thepurplepim.com.
TAGS NEW YORK–(BUSINESS WIRE)–Feb 17, 2021– Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma. The study evaluates the efficacy and safety of elranatamab, administered subcutaneously, in patients with disease that is refractory to at least one agent in each of three major classes of medications approved for multiple myeloma. The study’s estimated primary completion date is June 2022. Elranatamab has also been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Fast Track is a process designed to facilitate the development, and expedite the review, of new drugs and vaccines that are intended to treat or prevent serious conditions that have the potential to address an unmet medical need. 1 “The initiation of MagnetisMM-3, our pivotal trial, is an important step in our robust and accelerated development program for elranatamab,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. “Bispecific antibodies hold promise as the next potential breakthrough in the treatment of multiple myeloma. We are highly encouraged by early data with subcutaneous elranatamab, which was discovered and developed at Pfizer and designed to enhance safety and convenience.” At the Virtual American Society of Hematology (ASH) Annual Meeting and Exposition in December 2020, Pfizer presented encouraging data from an ongoing Phase 1 trial of elranatamab (MagnetisMM-1) demonstrating manageable safety and high response rates in patients with relapsed/refractory multiple myeloma including three patients whose disease relapsed on or progressed after prior BCMA-targeted therapies. At the highest dose level, which informed the dose selected for the Phase 2 study, 83% of patients achieved a clinical response. Safety was manageable across all subcutaneous dose levels with no dose-limiting toxicities observed. Bispecific antibodies are a novel type of cancer immunotherapy that bind to and engage two different targets at once. One arm binds directly to specific antigens on cancer cells and the other activates and brings a person’s own T-cells from the immune system closer to kill the cancer cells. Elranatamab is a bispecific antibody designed to bind to BCMA which is highly expressed on the surface of multiple myeloma cells, and the CD3 receptor found on the surface of cancer-fighting T-cells, bridging them together to activate an immune response. Binding affinity to BCMA and CD3 has been optimized, to potentially elicit more potent T-cell-mediated anti-myeloma activity. Subcutaneous administration of elranatamab is intended to allow higher doses than intravenous administration without increasing adverse events. In addition to MagnetisMM-3, other trials of elranatamab in multiple myeloma are planned both as monotherapy and in combination with standard or novel therapies. “Second and later relapses are unfortunately all too common in multiple myeloma and can be devastating to patients as remissions tend to be shorter and the disease may be more aggressive, 2 ” said Alexander M. Lesokhin, M.D., lead investigator and hematologic oncologist at Memorial Sloan Kettering Cancer Center. “Targeting BCMA is a promising area of innovation in multiple myeloma.” “Living with multiple myeloma can often be a roller coaster, of both hope and disappointment. It can be so up and down and nerve wracking as it’s often the case that a new treatment gets started, only to end in another relapse,” said Susie Novis Durie, Founder & President of the International Myeloma Foundation. “Continued research to develop new treatments with novel mechanisms of action is essential to improve outcomes for these patients.” About the MagnetisMM-3 Phase 2 Trial MagnetisMM-3 is an open-label, multicenter, nonrandomized Phase 2 study of elranatamab monotherapy enrolling approximately 150 people with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody. This study will enroll two cohorts of participants: one with (n=90) and one without (n=60) prior treatment with a BCMA-directed ADC or CAR-T therapy (n=60). Participants will receive a weekly 76 mg subcutaneous injection of elranatamab following a priming dose of 44 mg. The primary endpoint is objective response rate as assessed by blinded independent central review. Key secondary endpoints include: duration of response, progression-free survival, minimal residual disease negativity rate, overall survival and safety. For more information about the trial, visit www.clinicaltrials.gov. About Multiple Myeloma Multiple myeloma is a blood cancer that affects plasma cells made in the bone marrow. Healthy plasma cells make antibodies that help the body fight infection. According to the latest figures available, there are approximately 32,270 new cases of multiple myeloma diagnosed annually in the U.S and 176,000 globally. 3,4 Despite treatment advances, multiple myeloma remains incurable. The median survival is just over 5 years, and most patients receive four or more lines of therapy. 5 About Pfizer Oncology At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. DISCLOSURE NOTICE: The information contained in this release is as of February 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about elranatamab, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications for any potential indications for elranatamab may be filed in any jurisdictions; whether and when regulatory authorities in any jurisdictions may approve any such applications, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether elranatamab will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of elranatamab; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. # # # # # Dr. Lesokhin has a consulting relationship with Pfizer. 1 U.S. Food and Drug Administration. Fast Track. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track 2 Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematolog y Am Soc Hematol Educ Program. 2017(1): 508–517. doi: 10.1182/asheducation-2017.1.508 3 American Cancer Society. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html. Accessed January 2021 . 4 World Health Organization. Globocan 2020: Multiple Myeloma. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf. Accessed January 2021. 5 Mikhael, J, Ismaila N, Cheung M, et al . Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 37:1228-1263. View source version on businesswire.com:https://www.businesswire.com/news/home/20210217005121/en/ CONTACT: Media Contact: Eamonn Nolan +1 (978) 273-3946 [email protected] Investor Contact: Bryan Dunn +1 (212) 733-8917 [email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH FDA CLINICAL TRIALS SOURCE: Pfizer Inc. Copyright Business Wire 2021. PUB: 02/17/2021 06:45 AM/DISC: 02/17/2021 06:45 AM http://www.businesswire.com/news/home/20210217005121/en WhatsApp Previous articleNational Vision Holdings, Inc. Announces Fourth Quarter 2020 Earnings Release and Conference CallNext articleGlobal High-Speed Camera Market (2020 to 2026) – by Frame Rate, Application, Spectrum, Component and Region – ResearchAndMarkets.com Digital AIM Web Support Twitter Local NewsBusiness Facebook Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma Twitter By Digital AIM Web Support – February 17, 2021 Facebook Pinterest WhatsApp Pinterest
Pinterest WhatsApp Twitter TAGS By Digital AIM Web Support – March 19, 2021 Facebook Facebook [Abbildung 2] Der 25Gbps VCSEL (links) und der 100Gbps 4-Kanal VCSEL (rechts) von Seoul Viosys WhatsApp Pinterest Local News Twitter Seoul Viosys beginnt mit Massenproduktion von 25-Gbit/s-VCSELs für 5G-Kommunikationsanwendungen Previous articleOAT021521_winter_wildart_43Next articleGobert, Jazz beat Bucks 129-115 for 6th straight win Digital AIM Web Support